These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 37978055)

  • 21. Efficacy of topical cysteamine in nephropathic cystinosis.
    Al-Hemidan A; Shoughy SS; Kozak I; Tabbara KF
    Br J Ophthalmol; 2017 Sep; 101(9):1234-1237. PubMed ID: 28057644
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term treatment of infantile nephropathic cystinosis with cysteamine.
    da Silva VA; Zurbrügg RP; Lavanchy P; Blumberg A; Suter H; Wyss SR; Lüthy CM; Oetliker OH
    N Engl J Med; 1985 Dec; 313(23):1460-3. PubMed ID: 4058549
    [No Abstract]   [Full Text] [Related]  

  • 23. Negligible urinary cysteamine loss in cystinosis patients with Fanconi syndrome.
    Levtchenko EN; de Graaf-Hess A; Blom HJ; Monnens LA
    Clin Nephrol; 2002 May; 57(5):349-51. PubMed ID: 12036193
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Outcome of infantile nephropathic cystinosis depends on early intervention, not genotype: A multicenter sibling cohort study.
    Veys K; Zadora W; Hohenfellner K; Bockenhauer D; Janssen MCH; Niaudet P; Servais A; Topaloglu R; Besouw M; Novo R; Haffner D; Kanzelmeyer N; Pape L; Wühl E; Harms E; Awan A; Sikora P; Ariceta G; van den Heuvel B; Levtchenko E
    J Inherit Metab Dis; 2023 Jan; 46(1):43-54. PubMed ID: 36117148
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Biomarkers in Nephropathic Cystinosis: Current and Future Perspectives.
    Emma F; Montini G; Pennesi M; Peruzzi L; Verrina E; Goffredo BM; Canalini F; Cassiman D; Rossi S; Levtchenko E
    Cells; 2022 Jun; 11(11):. PubMed ID: 35681534
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Report of a Brazilian multicenter study on nephropathic cystinosis.
    Vaisbich MH; Koch VH
    Nephron Clin Pract; 2010; 114(1):c12-8. PubMed ID: 19816039
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cystinosis: clinical presentation, pathogenesis and treatment.
    Ivanova E; De Leo MG; De Matteis MA; Levtchenko E
    Pediatr Endocrinol Rev; 2014 Sep; 12 Suppl 1():176-84. PubMed ID: 25345100
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cysteamine therapy delays the progression of nephropathic cystinosis in late adolescents and adults.
    Brodin-Sartorius A; Tête MJ; Niaudet P; Antignac C; Guest G; Ottolenghi C; Charbit M; Moyse D; Legendre C; Lesavre P; Cochat P; Servais A
    Kidney Int; 2012 Jan; 81(2):179-89. PubMed ID: 21900880
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effects of transitioning from immediate release to extended release cysteamine therapy in Norwegian patients with nephropathic cystinosis: a retrospective study.
    Bjerre A; Aase SA; Radtke M; Siva C; Gudmundsdottir H; Forsberg B; Woldseth B; Brackman D
    Pediatr Nephrol; 2023 Nov; 38(11):3671-3679. PubMed ID: 37219641
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A randomized controlled crossover trial with delayed-release cysteamine bitartrate in nephropathic cystinosis: effectiveness on white blood cell cystine levels and comparison of safety.
    Langman CB; Greenbaum LA; Sarwal M; Grimm P; Niaudet P; Deschênes G; Cornelissen E; Morin D; Cochat P; Matossian D; Gaillard S; Bagger MJ; Rioux P
    Clin J Am Soc Nephrol; 2012 Jul; 7(7):1112-20. PubMed ID: 22554716
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Parenchymal organ cystine depletion with long-term cysteamine therapy.
    Gahl WA; Charnas L; Markello TC; Bernardini I; Ishak KG; Dalakas MC
    Biochem Med Metab Biol; 1992 Dec; 48(3):275-85. PubMed ID: 1476793
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical and neurophysiological characterization of early neuromuscular involvement in children and adolescents with nephropathic cystinosis.
    Elkhateeb N; Selim R; Soliman NA; Atia FM; Abouelwoun II; Elmonem MA; Helmy R
    Pediatr Nephrol; 2022 Jul; 37(7):1555-1566. PubMed ID: 34791528
    [TBL] [Abstract][Full Text] [Related]  

  • 33. NIH conference. Cystinosis: progress in a prototypic disease.
    Gahl WA; Thoene JG; Schneider JA; O'Regan S; Kaiser-Kupfer MI; Kuwabara T
    Ann Intern Med; 1988 Oct; 109(7):557-69. PubMed ID: 3048161
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Controversies and research agenda in nephropathic cystinosis: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference.
    Langman CB; Barshop BA; Deschênes G; Emma F; Goodyer P; Lipkin G; Midgley JP; Ottolenghi C; Servais A; Soliman NA; Thoene JG; Levtchenko EN;
    Kidney Int; 2016 Jun; 89(6):1192-203. PubMed ID: 27181776
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chitotriosidase as a Novel Biomarker for Therapeutic Monitoring of Nephropathic Cystinosis.
    Veys KRP; Elmonem MA; Van Dyck M; Janssen MC; Cornelissen EAM; Hohenfellner K; Prencipe G; van den Heuvel LP; Levtchenko E
    J Am Soc Nephrol; 2020 May; 31(5):1092-1106. PubMed ID: 32273301
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Multinucleated podocytes as a clue to diagnosis of juvenile nephropathic cystinosis.
    Ogata A; Deki S; Uchimura T; Inaba A; Otani M; Ito S
    Pediatr Nephrol; 2024 Feb; 39(2):609-612. PubMed ID: 37572116
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nephropathic cystinosis: posterior segment manifestations and effects of cysteamine therapy.
    Tsilou ET; Rubin BI; Reed G; Caruso RC; Iwata F; Balog J; Gahl WA; Kaiser-Kupfer MI
    Ophthalmology; 2006 Jun; 113(6):1002-9. PubMed ID: 16603246
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Improved prognosis of cystinosis achieved by treatment with cysteamine and by kidney transplantation].
    Oczachowska-Kulik AE; Lund AM; Skovby F; Pedersen EB
    Ugeskr Laeger; 2011 Aug; 173(33):1958-62. PubMed ID: 21849135
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nephropathic cystinosis in adults: natural history and effects of oral cysteamine therapy.
    Gahl WA; Balog JZ; Kleta R
    Ann Intern Med; 2007 Aug; 147(4):242-50. PubMed ID: 17709758
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Suppository formulations as a potential treatment for nephropathic cystinosis.
    Buchan B; Kay G; Matthews KH; Cairns D
    J Pharm Sci; 2012 Oct; 101(10):3729-38. PubMed ID: 22778070
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.